FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Evidence dossier
Intelligence passport
Measured timeline
-
Detected
-
Latest coverage observed
-
Evidence threshold reached
-
Peak measured velocity
-
Outcome review added
The reporting (5)
-
CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor TThe National Law Review · 113d ago
-
-
Biotech Stocks Facing FDA Decision In August 2026RTTNews · 113d ago
-
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLCGlobeNewswire · 113d ago
-
FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapyBioSpace · 113d ago
The brief
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
FDA staff have raised data concerns and disputed claims of Phase 3 success for Capricor's DMD cell therapy, deramiocel. This development has led to a significant drop in share price, with reports indicating the stock is on track for its worst day ever.
Coverage from BioSpace, Yahoo Finance, and RTTNews emphasizes the "ugly picture" painted by FDA documents and a divide among analysts regarding the probability of the therapy's approval. Legal scrutiny has also emerged, as the Kehoe Law Firm and Holzer & Holzer, LLC have announced investigations into the company.
Attention now turns to August 2026, when a decision from the FDA is expected.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 113d ago.
Quick answers
What therapy is the FDA questioning?
The FDA is disputing claims of Phase 3 success for deramiocel, a cell therapy for DMD.
How has the market reacted to the news?
Shares of Capricor Therapeutics (CAPR) have plunged, with analysts noting it is on track for its worst day ever.
What legal actions have been initiated?
Both the Kehoe Law Firm, P.C. and Holzer & Holzer, LLC have announced investigations into Capricor Therapeutics.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
The GLP-1 boom has a dark side
The FDA has ordered new eye-risk warnings on a dozen GLP-1 drugs including Ozempic and Zepbound, escalating safety scrutiny of the blockbuster weight-loss class.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The FDA has ordered new warning labels on blockbuster GLP-1 drugs Ozempic and Zepbound over a rare eye condition linked to sudden blindness, shaking confidence in the red-hot weight-loss market.
‘I’m destroyed.’ Owner speaks on E. coli outbreak that shut down SLO County farm
Brookshire Farms faces shutdown after an E. coli outbreak sickens fifteen, including three children with kidney failure, and co‑owner declares 'I'm destroyed'.
DEA And Marijuana Rescheduling Opponents File Final Briefs In Hearing Ahead Of Judge's Decision
Judge's decision looms on marijuana rescheduling as opponents file final briefs.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The FDA approved Hibsago, the first drug offering a functional cure for chronic hepatitis B, after clinical trials showed 19% of patients achieved undetectable virus levels that persisted after treatment ended.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.